142 related articles for article (PubMed ID: 6580906)
1. Role of the fast-exchanging calcium compartment in the early cardiotoxicity of anthracycline analogs.
Monti E; Piccinini F; Favalli L; Villani F
Biochem Pharmacol; 1983 Nov; 32(22):3303-6. PubMed ID: 6580906
[TBL] [Abstract][Full Text] [Related]
2. Relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4'-epi-doxorubicin in guinea pig heart muscle.
Villani F; Favalli L; Piccinini F
Tumori; 1980 Dec; 66(6):689-97. PubMed ID: 6940313
[TBL] [Abstract][Full Text] [Related]
3. Preliminary evaluation of myocardial toxicity of 4'-deoxydoxorubicin: experimental and clinical results.
Villani F; Comazzi R; Genitoni V; Lacaita G; Guindani A; Crippa F; Monti E; Piccinini F; Rozza A; Lanza E
Drugs Exp Clin Res; 1985; 11(3):223-31. PubMed ID: 3836127
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
[TBL] [Abstract][Full Text] [Related]
5. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function.
Mushlin PS; Cusack BJ; Boucek RJ; Andrejuk T; Li X; Olson RD
Br J Pharmacol; 1993 Nov; 110(3):975-82. PubMed ID: 8298821
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations.
Chugun A; Uchide T; Tsurimaki C; Nagasawa H; Sasaki T; Ueno S; Takagishi K; Hara Y; Temma K
J Vet Med Sci; 2008 Mar; 70(3):255-64. PubMed ID: 18388425
[TBL] [Abstract][Full Text] [Related]
7. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
Chen ZM; Colombo T; Conforti L; Grazia Donelli M; Fiedorowicz RJ; Marchi S; Paolini A; Riva E; Zuanetti G; Latini R
J Pharm Pharmacol; 1987 Nov; 39(11):947-50. PubMed ID: 2892924
[TBL] [Abstract][Full Text] [Related]
8. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
9. Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart.
Zucchi R; Yu G; Ghelardoni S; Ronca F; Ronca-Testoni S
Br J Pharmacol; 2000 Sep; 131(2):342-8. PubMed ID: 10991929
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart.
Temma K; Akera T; Chugun A; Kondo H; Hagane K; Hirano S
Eur J Pharmacol; 1993 Apr; 234(2-3):173-81. PubMed ID: 8482324
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity of anthracyclines.
Bossa R; Efstathiu G; Galatulas I; Nilnci MA
In Vivo; 1991; 5(1):61-3. PubMed ID: 1932627
[TBL] [Abstract][Full Text] [Related]
13. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
14. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Gianni L; Minotti G
J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
[TBL] [Abstract][Full Text] [Related]
15. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
16. The rat model in the comparative evaluation of anthracyclines cardiotoxicity.
Lanza E; Rozza A; Favalli L; Monti E; Poggi P; Villani F
Tumori; 1989 Dec; 75(6):533-6. PubMed ID: 2617699
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine receptor gene expression.
Gambliel HA; Burke BE; Cusack BJ; Walsh GM; Zhang YL; Mushlin PS; Olson RD
Biochem Biophys Res Commun; 2002 Mar; 291(3):433-8. PubMed ID: 11855807
[TBL] [Abstract][Full Text] [Related]
18. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
19. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.
Robert J
Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
